MHC INDUSTRIAL CO., LTD

According to the news of the Indian chamber of commerce and industry, India has gradually become the world's new drug clinical trials center. There are more than 100 local and international companies conducting clinical trials of newly developed drugs in India. The next five years, the industry with value of 80 billion rupees ($ 1.8 billion) will provide India with 50,000 job opportunities.

It is estimated that global clinical pharmaceutical research outsourcing market is $ 45 billion in value. It includes the value of outsourcing services of pharmaceutical manufacturers and biotechnology chia seed companies for research and development of innovative molecular medicine and general medicine. Recently, a large number of pharmaceutical patent protections will face maturity, many companies have accelerated the pace of clinical research and development in order to grab market opportunities. According to analysis, the world's major pharmaceutical companies will be more than 15 percent of the global clinical trials on new drugs in India.

National pharmaceutical companies has been swarming to India to conduct clinical trials of new drugs, because India has the following characteristics: a large number of sick people, a wide variety of diseases, low level of consumption, but also with highly educated professionals and sound patent protection laws.

India tax preferential policies to attract pharmaceutical companies to the new drug clinical trials outsourcing to India one of the reasons, the provisions of the Government of India to give 10 years of tax breaks for corporate investment in R & D.

In addition, the major hospitals in India in recent years increase investment. There are a large number of electronic medical docetaxel equipment is introducing and installed. It provides patients with accurate electronic medical records, which is attracting national pharmaceutical companies to the human drug clinical trials outsourcing to India a major cause.